Literature DB >> 21617944

Arachidonic acid ω-hydroxylase CYP4A11: inter-ethnic variations in the 8590T>C loss-of-function variant.

Christian Lacks Lino Cardenas1, Aurore Devos, Aminata Toure, Jaime Cardenas Garcia, Abderraouf Kenani, Florence Migot-Nabias, Franck Broly, Dany Chevalier.   

Abstract

The human Cytochrome P450 4A11 (CYP4A11) is a major ω-hydroxylase involved in the regulation of blood pressure in the kidney through the conversion of arachidonic acid into 20-hydroxyeicosatetraenoic acid (20-HETE). Previous studies have reported a significant association between the 8590T>C genetic variant of CYP4A11 and hypertension. Interestingly, several population-based studies have reported ethnic differences in the prevalence of hypertension, with the highest prevalence in African populations. The aim of this work was to determine the frequency and inter-ethnic comparison of the CYP4A11 (8590T>C) functional polymorphism, in five new ethnic groups: European (99 French Caucasians), African (36 Gabonese and 50 Senegalese), South American (60 Peruvians) and North African (53 Tunisians) populations, using polymerase chain reaction-single strand conformational polymorphism and sequencing strategies. We confirmed that the CYP4A11 (8590T>C) functional polymorphism exhibits inter-ethnic frequency differences. Noteworthy, the highest 8590C allele frequency was observed in the Tunisian (30.2%), followed by Senegalese (20%) populations. In addition, the CC genotype was only found in the Gabonese and Tunisian populations (5.6% and 8.4%, respectively). These populations may be of major interest to help to clarify the linkage between hypertension and CYP4A11 (8590T>C) genotype in African populations. These findings provide data for further studies that investigate the potential association of CYP4A11 (8590T>C) variant with an incidence of hypertension genesis in respect of ethnicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21617944     DOI: 10.1007/s11033-011-0888-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  29 in total

1.  Differential regulation of human CYP4A genes by peroxisome proliferators and dexamethasone.

Authors:  Uzen Savas; Mei-Hui Hsu; Eric F Johnson
Journal:  Arch Biochem Biophys       Date:  2003-01-01       Impact factor: 4.013

2.  Characterization of the CYP4A11 gene, a second CYP4A gene in humans.

Authors:  Aouatef Bellamine; Yarong Wang; Michael R Waterman; James V Gainer; Elliot P Dawson; Nancy J Brown; Jorge H Capdevila
Journal:  Arch Biochem Biophys       Date:  2003-01-01       Impact factor: 4.013

3.  Cytochrome P450 nomenclature, 2004.

Authors:  David R Nelson
Journal:  Methods Mol Biol       Date:  2006

4.  Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension.

Authors:  James V Gainer; Aouatef Bellamine; Elliott P Dawson; Kristie E Womble; Sarah W Grant; Yarong Wang; L Adrienne Cupples; Chao-Yu Guo; Serkalem Demissie; Christopher J O'Donnell; Nancy J Brown; Michael R Waterman; Jorge H Capdevila
Journal:  Circulation       Date:  2004-12-20       Impact factor: 29.690

5.  Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms.

Authors:  M Orita; H Iwahana; H Kanazawa; K Hayashi; T Sekiya
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

Review 6.  20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure.

Authors:  J C McGiff; J Quilley
Journal:  Curr Opin Nephrol Hypertens       Date:  2001-03       Impact factor: 2.894

7.  Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction.

Authors:  Björn Mayer; Wolfgang Lieb; Anika Götz; Inke R König; Lena F Kauschen; Patrick Linsel-Nitschke; Andrea Pomarino; Stephan Holmer; Christian Hengstenberg; Angela Doering; Hannelore Loewel; Hans-Werner Hense; Andreas Ziegler; Jeanette Erdmann; Heribert Schunkert
Journal:  J Hypertens       Date:  2006-10       Impact factor: 4.844

8.  Association of a CYP4A11 variant and blood pressure in black men.

Authors:  James V Gainer; Michael S Lipkowitz; Chang Yu; Michael R Waterman; Elliott P Dawson; Jorge H Capdevila; Nancy J Brown
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

9.  Cytochrome P450 4A expression and arachidonic acid omega-hydroxylation in the kidney of the spontaneously hypertensive rat.

Authors:  M L Schwartzman; J L da Silva; F Lin; M Nishimura; N G Abraham
Journal:  Nephron       Date:  1996       Impact factor: 2.847

10.  A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure.

Authors:  Natalie C Ward; I-Jung Tsai; Anne Barden; Frank M van Bockxmeer; Ian B Puddey; Jonathan M Hodgson; Kevin D Croft
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

View more
  4 in total

1.  Role of 20-HETE in the antihypertensive effect of transfer of chromosome 5 from Brown Norway to Dahl salt-sensitive rats.

Authors:  Jan M Williams; Fan Fan; Sydney Murphy; Carlos Schreck; Jozef Lazar; Howard J Jacob; Richard J Roman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-03-21       Impact factor: 3.619

Review 2.  Vascular actions of 20-HETE.

Authors:  Samantha L Hoopes; Victor Garcia; Matthew L Edin; Michal L Schwartzman; Darryl C Zeldin
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-03-23       Impact factor: 3.072

Review 3.  Arachidonic acid monooxygenase: Genetic and biochemical approaches to physiological/pathophysiological relevance.

Authors:  Jorge H Capdevila; Wenhui Wang; John R Falck
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-05-15       Impact factor: 3.072

Review 4.  20-HETE and blood pressure regulation: clinical implications.

Authors:  Cheng-Chia Wu; Tanush Gupta; Victor Garcia; Yan Ding; Michal L Schwartzman
Journal:  Cardiol Rev       Date:  2014 Jan-Feb       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.